Ovarian cancer screening: Current status and future directions

Z Nash, U Menon - Best practice & research Clinical obstetrics & …, 2020 - Elsevier
Ovarian cancer is the third most common gynaecological malignancy and the most lethal
worldwide. Most patients are diagnosed with advanced disease which carries significant …

Cancer genetics, precision prevention and a call to action

C Turnbull, A Sud, RS Houlston - Nature genetics, 2018 - nature.com
More than 15 years have passed since the identification, through linkage, of 'first-
wave'susceptibility genes for common cancers (BRCA1, BRCA2, MLH1 and MSH2). These …

CanRisk Tool—A web interface for the prediction of breast and ovarian cancer risk and the likelihood of carrying genetic pathogenic variants

T Carver, S Hartley, A Lee, AP Cunningham… - … , biomarkers & prevention, 2021 - AACR
Abstract Background: The CanRisk Tool (https://canrisk. org) is the next-generation web
interface for the latest version of the BOADICEA (Breast and Ovarian Analysis of Disease …

Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer

CM Phelan, KB Kuchenbaecker, JP Tyrer, SP Kar… - Nature …, 2017 - nature.com
To identify common alleles associated with different histotypes of epithelial ovarian cancer
(EOC), we pooled data from multiple genome-wide genoty** projects totaling 25,509 EOC …

Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D

X Yang, H Song, G Leslie, C Engel… - JNCI: Journal of the …, 2020 - academic.oup.com
Background The purpose of this study was to estimate precise age-specific tubo-ovarian
carcinoma (TOC) and breast cancer (BC) risks for carriers of pathogenic variants in RAD51C …

Cost-effectiveness of population-based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 mutation testing in unselected general population women

R Manchanda, S Patel, VS Gordeev… - JNCI: Journal of the …, 2018 - academic.oup.com
Background The cost-effectiveness of population-based panel testing for high-and moderate-
penetrance ovarian cancer (OC)/breast cancer (BC) gene mutations is unknown. We …

The DNA methylome of cervical cells can predict the presence of ovarian cancer

JE Barrett, A Jones, I Evans, D Reisel, C Herzog… - Nature …, 2022 - nature.com
The vast majority of epithelial ovarian cancer arises from tissues that are embryologically
derived from the Müllerian Duct. Here, we demonstrate that a DNA methylation signature in …

Comprehensive epithelial tubo-ovarian cancer risk prediction model incorporating genetic and epidemiological risk factors

A Lee, X Yang, J Tyrer, A Gentry-Maharaj… - Journal of medical …, 2022 - jmg.bmj.com
Background Epithelial tubo-ovarian cancer (EOC) has high mortality partly due to late
diagnosis. Prevention is available but may be associated with adverse effects. A …

Economic Evaluation of Population-Based BRCA1/BRCA2 Mutation Testing across Multiple Countries and Health Systems

R Manchanda, L Sun, S Patel, O Evans, J Wilschut… - Cancers, 2020 - mdpi.com
Clinical criteria/Family history-based BRCA testing misses a large proportion of BRCA
carriers who can benefit from screening/prevention. We estimate the cost-effectiveness of …

Enhancing the BOADICEA cancer risk prediction model to incorporate new data on RAD51C, RAD51D, BARD1 updates to tumour pathology and cancer incidence

A Lee, N Mavaddat, A Cunningham, T Carver… - Journal of medical …, 2022 - jmg.bmj.com
Background BOADICEA (Breast and Ovarian Analysis of Disease Incidence and Carrier
Estimation Algorithm) for breast cancer and the epithelial tubo-ovarian cancer (EOC) models …